To support innovation and excellence in cancer research, the Montreal Cancer Institute is investing in the acquisition of cutting-edge equipment: the Incucyte S3X, along with a specialized incubator.
This advanced technological tool, utilized by over 14 research teams, will enhance the Institute’s scientific capabilities and support innovative projects. With this strategic investment, researchers will have the necessary resources to pursue their work and push the boundaries of oncology knowledge.
This project was made possible thanks to funds raised during the 2024 Masquerade Gala and a direct financial commitment from the Institute. This investment highlights the Institute’s dedication to advancing cutting-edge research to better understand and fight cancer.
Other news
